Press Releases

Press Releases

Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)

Songdo, S. Korea, 23 April 2020 –Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018. As a result, ImmuneOncia will begin Phase 1 clinical trials of the pipeline product. 

 

IMC-002 is an immune checkpoint inhibitor antibody, which blocks CD47-SIRP- α interaction between tumor cells and macrophages. According to ImmuneOncia, IMC-002 is expected to help patients with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. 

 

Leveraging Samsung Biologics’ global CDO capabilities, IMC-002 IND was approved by the FDA without significant comments. Samsung Biologics provided ImmuneOncia with services in cell line development, process development, non-clinical and clinical material production. 

 

Samsung Biologics is currently providing support to 51 CDO development projects and is distinctly able to help clients achieve the most optimal path to IND approval by providing Faster & Better services. Samsung’s presence as a CDO in the global biopharma market has demonstrated rapid growth, and the company has announced plans to expand geographically to support even more clients globally and domestically. 

 

"We are very impressed with the outstanding service Samsung Biologics provided in the full development scope - from cell line development, process development, preclinical and clinical manufacturing, and IND filing support," said Yun Jeong Song, CEO of ImmuneOncia. "The two companies collaborated exceptionally well together during the whole development process including the IND evaluation period, allowing us to enter phase I clinical trials for IMC-002 much quicker." 

 

“We are excited to join in ImmuneOncia’s success,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “This IND approval is the product of the strong collaboration between Samsung Biologics and ImmuneOncia. As a world-leading CMO, CDO and CRO partner, we will continue to support ImmuneOncia and ensure client satisfaction through Samsung’s competitive advantages: faster timeline, excellent quality, and outstanding capability.” 


About IMC-002 

IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47–SIRPα interaction in order to promote the phagocytosis of cancer cells by macrophages. It binds to human CD47 with an optimal affinity that maximizes efficacy without binding to RBCs or causing anemia which is often seen in other CD47 blocking agents under development. For more information about the upcoming Phase 1 clinical trial, visit clinicaltrials.gov, identifier number NCT04306224. 

 

About ImmuneOncia Therapeutics, Inc. 

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia leverages both companies’ expertise in drug development and antibody engineering. The company’s mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its portfolio includes diverse immune checkpoint antibodies. ImmuneOncia has successfully completed a Phase I study of IMC-001, its leading candidate anti-PDL1 antibody, and a multi-regional Phase II study is planned for 1H2020. For more information, visit www.immuneoncia.com. 

Songdo, S. Korea, 23 April 2020 –Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018. As a result, ImmuneOncia will begin Phase 1 clinical trials of the pipeline product. 

 

IMC-002 is an immune checkpoint inhibitor antibody, which blocks CD47-SIRP- α interaction between tumor cells and macrophages. According to ImmuneOncia, IMC-002 is expected to help patients with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. 

 

Leveraging Samsung Biologics’ global CDO capabilities, IMC-002 IND was approved by the FDA without significant comments. Samsung Biologics provided ImmuneOncia with services in cell line development, process development, non-clinical and clinical material production. 

 

Samsung Biologics is currently providing support to 51 CDO development projects and is distinctly able to help clients achieve the most optimal path to IND approval by providing Faster & Better services. Samsung’s presence as a CDO in the global biopharma market has demonstrated rapid growth, and the company has announced plans to expand geographically to support even more clients globally and domestically. 

 

"We are very impressed with the outstanding service Samsung Biologics provided in the full development scope - from cell line development, process development, preclinical and clinical manufacturing, and IND filing support," said Yun Jeong Song, CEO of ImmuneOncia. "The two companies collaborated exceptionally well together during the whole development process including the IND evaluation period, allowing us to enter phase I clinical trials for IMC-002 much quicker." 

 

“We are excited to join in ImmuneOncia’s success,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “This IND approval is the product of the strong collaboration between Samsung Biologics and ImmuneOncia. As a world-leading CMO, CDO and CRO partner, we will continue to support ImmuneOncia and ensure client satisfaction through Samsung’s competitive advantages: faster timeline, excellent quality, and outstanding capability.” 

 

About IMC-002 

IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47–SIRPα interaction in order to promote the phagocytosis of cancer cells by macrophages. It binds to human CD47 with an optimal affinity that maximizes efficacy without binding to RBCs or causing anemia which is often seen in other CD47 blocking agents under development. For more information about the upcoming Phase 1 clinical trial, visit clinicaltrials.gov, identifier number NCT04306224. 

 

About ImmuneOncia Therapeutics, Inc. 

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia leverages both companies’ expertise in drug development and antibody engineering. The company’s mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its portfolio includes diverse immune checkpoint antibodies. ImmuneOncia has successfully completed a Phase I study of IMC-001, its leading candidate anti-PDL1 antibody, and a multi-regional Phase II study is planned for 1H2020. For more information, visit www.immuneoncia.com.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION